Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
41 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Teva Pharma Belgium from Antwerpen, company number BE0451951110, closed financial year 2025 with a result of € 2.2 million after tax. For that financial year Teva Pharma Belgium recorded revenue of € 81.8 million and equity of € 6.7 million. Compared with financial year 2024, the result moved from € 1.6 million to € 2.2 million. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 2, 2026.
€ 6.7 million
▲ 48% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2.2 million
▲ 33% vs 2024
Profit after tax over the fiscal year.
€ 278
▼ 23% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 3.2 million.
People and assets in 2025
32.5
▲ 1.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 6.8 million
▲ 16% vs 2024
€ 209,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 7,030
▼ 63% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 9.2 million
▲ 119% vs 2024
Loans from banks and other lenders, long and short.
€ 14.9 million
▲ 19% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 95 days on average.
€ 2.6 million
▲ 27% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 52,294,507 | € 60,240,011 | € 75,152,448 | € 81,822,068 | ▲ 9% |
| Profit after taxes | € 1,004,256 | € 1,292,188 | € 1,634,248 | € 2,174,865 | ▲ 33% |
| Equity | € 4,500,000 | € 4,500,000 | € 4,500,000 | € 6,674,865 | ▲ 48% |
| Total debts | € 13,323,605 | € 19,411,509 | € 20,434,333 | € 26,732,443 | ▲ 31% |
| Cash | € 200,498 | € 43 | € 362 | € 278 | ▼ 23% |
| Retained profit | € 1,000,000 | € 1,000,000 | € 1,000,000 | € 3,174,865 | ▲ 217% |
| Dividend | € 13,113,996 | € 1,292,188 | € 1,634,248 | € 0 | ▼ 100% |
| Bank debt | € 0 | € 0 | € 4,179,045 | € 9,171,323 | ▲ 119% |
| Balance sheet total | € 17,823,605 | € 23,911,509 | € 24,934,333 | € 33,407,308 | ▲ 34% |
| Employees (FTE) | 32.8 | 32.7 | 31.4 | 32.5 | ▲ 1.1 |
Key figures of Teva Pharma Belgium, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Teva Pharma Belgium?
What happened at Teva Pharma Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Ines Marinovic stepped down as director. NBB
- Michiel Letteboer stepped down as director. NBB
- Jan Willem Scheer stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 2.2 million (▲ 33% vs 2024). Source: NBB ↗
- Michiel Letteboer became a director. NBB
- Jan Willem Scheer became a director. NBB
- Ines Marinovic became a director. NBB
- New establishment in Antwerpen. KBO
In short
From € 1 million profit in 2022 to € 2.2 million profit in 2025.
Paid € 2.3 million in corporate taxes since 2022.
Best year ever: 2025, with € 2.2 million profit.
Paid out € 16 million in dividends to the owners in total.
Management
Directors
According to the 2025 annual accounts
Ines Marinovic
Director
since 2023 · until 2028
Michiel Letteboer
Director
since 2025 · until 2028
Jan Willem Scheer
Director
since 2025 · until 2028
Establishments
Establishment units
Physical locations of this company
Sneeuwbeslaan 20 box 20
2610 Antwerpen
Laarstraat 16
2610 Antwerpen
Active since 1 January 2016
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 41 companies are registered at this address.
All companies at this address →Association belge des Analystes financiers - Belgische Vereniging der Financiële Analisten
€ -15,281 gross margin · 2025
ETION Synergia
€ -1.1 million gross margin · 2025
Mediwe
€ 3.3 million revenue · 2025
MCS
€ 4.9 million revenue · 2025
BURGER BRANDS BELGIUM
€ 51.1 million revenue · 2021
+36 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0451.951.110
- VAT number
- BE 0451.951.110
- Registered office
- Sneeuwbeslaan 20 bus 20, 2610 Antwerpen
- Names & denominations
- Teva Pharma Belgium · Teva
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 3 February 1994
- Peppol
- Active · Active since 8 Dec 2025
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Groothandel in chemische producten voor industrieel gebruik
Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden
Vervaardiging van niet-elektrische apparaten en instrumenten voor de geneeskunde, de tandheelkunde en de veeartsenijkunde
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Groothandel in chemische producten
+1